National Cancer Institute
at the National Institutes of Health
Information Summary from PDQ
- Clinical Trials to Treat Prostate Cancer
Check for prostate cancer treatment trials from NCI's list of cancer clinical trials now accepting patients. The list of clinical trials can be refined by location, stage of disease, drug, and other features.
General Information About Prostate Cancer Treatment
- Radium-223 Improves Survival in Patients with Advanced Prostate Cancer
Results from a phase III trial show that radium-223 dichloride (Xofigo®) improves overall survival in men with advanced prostate cancer that has spread to their bones compared with placebo.
- Observation as Good as Surgery for Some Men with Prostate Cancer
Many men diagnosed with early-stage prostate cancer could forego radical prostatectomy and live as long as men who have immediate surgery, according to long-awaited results from a clinical trial published July 19, 2012, in the New England Journal of Medicine (NEJM).
- Abiraterone Improves Survival in Metastatic Prostate Cancer
A multinational phase III trial found that the drug abiraterone acetate prolonged the median survival of patients with metastatic castration-resistant prostate cancer by 4 months compared with patients who received a placebo.
- NIH-funded study shows reduction in death for men with intermediate-grade prostate cancer:
Short-term hormone therapy given in combination with radiation therapy to men with early-stage prostate cancer increased their chances of living longer compared to treatment with radiation therapy alone, according to a clinical trial supported by NCI. Benefits of the combined treatment were limited mainly to patients with intermediate-risk disease and were not seen for men with low-risk prostate cancer, researchers say.
- Denosumab Reduces Risk of Bone Side Effects in Advanced Prostate Cancer
The biological agent denosumab (Xgeva) is more effective than zoledronic acid at decreasing the risk of bone fractures and other skeletal-related events (SRE) in men with castration-resistant metastatic prostate cancer, according to results from a randomized clinical trial reported online February 25, 2011, in The Lancet.
- New Drug Benefits Patients with Advanced Prostate Cancer
The drug cabazitaxel improves the survival of some patients with advanced prostate cancer compared with those who receive standard chemotherapy.
- Adding Radiation to Hormone Therapy Improves Survival in Locally Advanced Prostate Cancer
Adding radiotherapy to androgen deprivation therapy (ADT) improves survival in men with locally advanced prostate cancer, according to findings presented at the 2010 ASCO meeting in Chicago.
- PSA Screening Leads to Aggressive Treatment, Even in Older Men at Low Risk
Screening for prostate cancer with the prostate-specific antigen (PSA) test has led to overtreatment of many prostate cancers, including aggressive treatments in older men considered to be at low risk for progression of the disease according to a study published in the July 26, 2010 Archives of Internal Medicine.
Related Treatment Information
- Cancer Vaccines
A fact sheet that discusses cancer vaccines. Explains how they work, how they are made, and describes research related to their use.
- Radiation Therapy for Cancer
A fact sheet that defines the different types of radiation therapy and discusses scientific advances that improve the effectiveness of this treatment.
- Cryosurgery in Cancer Treatment: Questions and Answers
A fact sheet that describes cryosurgery, the technique of using extreme cold to treat tumors. Lists the indications, risks, benefits, and side effects of cryotherapy.
- Metastatic Cancer
A fact sheet about metastasis, the spread of cancer to other parts of the body. Discusses the diagnosis and treatment of cancer that has spread.